Comparison of granisetron with sufentanil effect on reducing the severity of myoclonus movements due to intravenous etomidate prescription in educational hospitals of Mashhad University of Medical Sciences
Phase 3
Recruiting
- Conditions
- -Intensity of Myoclonus movements.
- Registration Number
- IRCT20210221050436N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Elective surgery
ASA I,II .
Age between 15-60 years
Having anesthesia condition
Exclusion Criteria
1- Adrenal dysfunction-
Sensitivity to drugs
Mental disorders
Neuromuscular disease
Convulsions
Electrolyte disorders
History of addiction
Prolonged QT and cardiovascular disease
High ICP and IOP
Increased intra-abdominal pressure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intensity of myoclonus movements after intravenous injection of etomidate. Timepoint: Once immediately after intravenous etomidate. Method of measurement: Myoclonus intensity with a score between 0 and 3 including 0 (without myoclonus), 1 or mild (gentle movements of a part of the body such as finger or wrist), 2 or moderate (gentle movements of 2 different muscle groups such as face and legs), 3 or severe (movements Severe clonic is measured in 2 or more muscle groups or rapid limb adduction).
- Secondary Outcome Measures
Name Time Method Vital Sign Measurement (MAP). Timepoint: MAP is measured and recorded 60 seconds before and after injection of each drug under study (sufentanil and granisterone). Method of measurement: Through monitoring connected to the patient.;Vital Sign Measurement (HR). Timepoint: HR is measured and recorded 60 seconds before and after injection of each drug under study (sufentanil and granisterone). Method of measurement: Through monitoring connected to the patient.